Sanger scales up on protein interaction - News - Academia and Research - Business Weekly

HOME

Sanger scales up on protein interaction

Written by Sam Fountain
Friday, 29 February 2008
A new large-scale method that can reveal drug targets by studying the interactions between proteins that are a major target for therapeutic intervention has been developed by scientists at the the Wellcome Trust Sanger Institute near Cambridge. The novel method, called AVEXIS, can identify the weak, short-lived interactions that are characteristic of cell responses to cues from the environment or from within the body and the team hopes it will uncover many important interactions that are invisible to current detection methods. Cell surface proteins are targets for many drugs and are central to many processes of cell regulation, such as some cancer therapeutics, diabetes, and growth. Using human proteins and zebrafish as a model, the Sanger Institute researchers looked at interactions between 110 proteins in this superfamily – a total of more than 6000 experiments. Set as favorite Bookmark Email This Hits: 248 Trackback(0) TrackBack URI for this entry Comments (0) Subscribe to this comment's feed Show/Hide comments Write comment Show/Hide comment form This content has been locked. You can no longer post any comment.